Protalix BioTherapeutics (PLX) Operating Margin (2010 - 2026)
Protalix BioTherapeutics' quarterly Operating Margin came in at 62.65% in Q1 2026, up 10364.0% year-on-year from N/an in Q1 2025, and up 1801.0% quarter-over-quarter from 3.68% in Q4 2025.
Protalix BioTherapeutics has reported Operating Margin for 17 years, with the latest figure at 62.65% in Q1 2026.
- For the quarter ending Q1 2026, Operating Margin rose 10364.0% year-over-year to 62.65%; the trailing twelve-month figure through Mar 2026 stood at 31.57% (up 2383.0% YoY), and the FY2025 full-year result was 2.23%, down 957.0% from the prior year.
- Operating Margin for Q1 2026 stood at 62.65%, up from 3.68% in the prior quarter.
- The five-year high for Operating Margin was 86.99% in Q4 2022, with the low at 129.56% in Q1 2024.
- Average Operating Margin over 5 years is 5.73%, with a median of 11.63% recorded in 2022.
- Year-over-year, Operating Margin surged 15374 bps in 2022 and tumbled 14054 bps in 2023.
- Tracing PLX's Operating Margin over 5 years: stood at 86.99% in 2022, then tumbled by 162 bps to 53.55% in 2023, then soared by 174 bps to 39.57% in 2024, then sank by 109 bps to 3.68% in 2025, then soared by 1801 bps to 62.65% in 2026.
- The last three Operating Margin figures came in at 62.65% (Q1 2026), 3.68% (Q4 2025), and 11.94% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 62.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62.65% |
| Dec 31, 2025 | -3.68% |
| Sep 30, 2025 | 11.94% |
| Jun 30, 2025 | 7.48% |
| Mar 31, 2025 | -40.99% |
| Dec 31, 2024 | 39.57% |
| Sep 30, 2024 | 22.22% |
| Jun 30, 2024 | -18.01% |
| Mar 31, 2024 | -129.56% |
| Dec 31, 2023 | -53.55% |
| Sep 30, 2023 | -18.24% |
| Jun 30, 2023 | 58.22% |
| Mar 31, 2023 | -25.65% |
| Dec 31, 2022 | 86.99% |
| Sep 30, 2022 | -22.03% |
| Jun 30, 2022 | -63.11% |
| Mar 31, 2022 | -11.63% |
| Dec 31, 2021 | -66.74% |
| Sep 30, 2021 | -15.64% |
| Jun 30, 2021 | -142.62% |
| Mar 31, 2021 | -32.73% |
| Dec 31, 2020 | 14.56% |
| Sep 30, 2020 | -23.93% |
| Jun 30, 2020 | -20.42% |
| Mar 31, 2020 | 21.68% |
| Dec 31, 2019 | 15.74% |
| Sep 30, 2019 | -10.84% |
| Jun 30, 2019 | -47.68% |
| Mar 31, 2019 | -53.01% |
| Dec 31, 2018 | -209.11% |
| Sep 30, 2018 | -564.25% |
| Jun 30, 2018 | -336.19% |
| Mar 31, 2018 | -113.13% |
| Dec 31, 2017 | -532.33% |
| Sep 30, 2017 | -103.18% |
| Jun 30, 2017 | -169.94% |
| Mar 31, 2017 | -386.70% |
| Dec 31, 2016 | -419.03% |
| Sep 30, 2016 | -142.36% |
| Jun 30, 2016 | -561.39% |
| Mar 31, 2016 | -1,158.17% |
| Sep 30, 2015 | -374.40% |
| Jun 30, 2015 | -417.96% |
| Mar 31, 2015 | -318.20% |
| Mar 31, 2014 | -96.59% |
| Dec 31, 2013 | 210.63% |
| Sep 30, 2013 | -247.15% |
| Jun 30, 2013 | -304.51% |
| Mar 31, 2013 | -124.13% |
| Dec 31, 2012 | -867.49% |
| Sep 30, 2012 | -149.30% |
| Jun 30, 2012 | 36.84% |
| Mar 31, 2012 | -157.08% |
| Dec 31, 2011 | -375.02% |
| Sep 30, 2011 | -774.47% |
| Jun 30, 2011 | -1,815.18% |
| Mar 31, 2011 | -122.04% |
| Dec 31, 2010 | -752.38% |
| Sep 30, 2010 | -89.45% |
| Jun 30, 2010 | -889.57% |